P21

Also known as: P021

**Mechanism of Action** P21 (P021) is a synthetic peptidergic compound derived from ciliary neurotrophic factor (CNTF). It acts as a selective agonist of the CNTF receptor complex, primarily modulating the JAK/STAT3 and MAPK/ERK signaling pathways. In preclinical models, P21 promotes hippocampal neurogenesis by enhancing neural stem cell proliferation and differentiation. Additionally, it reduces tau hyperphosphorylation and aggregation through activation of the PI3K/Akt/GSK-3β axis, thereby mitigating tau pathology—a hallmark of Alzheimer’s disease (AD). The peptide does not cross the blood-brain barrier efficiently, but direct central administration or intranasal delivery has shown efficacy in rodent studies. **Key Research Findings** Preclinical studies in transgenic AD mouse models (e.g., 3xTg-AD) demonstrate that P21 treatment significantly increases newborn neuron survival in the dentate gyrus, correlating with improved spatial memory and cognitive function in Morris water maze and novel object recognition tests. Biochemical analyses reveal reduced levels of phosphorylated tau (p-tau at Ser396/404) and decreased neurofibrillary tangle burden. Notably, P21 also attenuates neuroinflammation by lowering microglial activation and pro-inflammatory cytokine levels (IL-1β, TNF-α). However, long-term safety and dose-response data remain limited, and no human trials have been conducted. **Clinical Relevance** P21 represents a promising dual-action therapeutic candidate for AD, targeting both neurogenesis deficits and tau pathology—two core pathological features. Its CNTF-derived mechanism offers a novel approach distinct from amyloid-targeting strategies. However, clinical translation faces challenges, including the need for optimized delivery methods (e.g., intranasal or conjugated carriers) to achieve central nervous system bioavailability. Current evidence is confined to preclinical models, and further validation in larger animal studies and eventual Phase I trials is required to assess safety, pharmacokinetics, and efficacy in humans. For research purposes only — not medical advice.

Key data

Research & studies

Frequently asked questions

Related peptides